<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5546">
  <stage>Registered</stage>
  <submitdate>3/12/2009</submitdate>
  <approvaldate>3/12/2009</approvaldate>
  <nctid>NCT01025869</nctid>
  <trial_identification>
    <studytitle>The Clinical Evaluation of the Cinatra Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries</studytitle>
    <scientifictitle>The Clinical Evaluation of the Cinatra Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries</scientifictitle>
    <utrn />
    <trialacronym>VANTAGE-1</trialacronym>
    <secondaryid>902</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Cinatra Corolimus Eluting Coronary Stent System

Other: Stent System - Cinatra Corolimus Eluting Coronary Stent System


Treatment: devices: Cinatra Corolimus Eluting Coronary Stent System
Stent implantation

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>In-stent late lumen loss (LLL) as measured by quantitative coronary angiography (QCA).</outcome>
      <timepoint>6 months post treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Target lesion revascularization</outcome>
      <timepoint>1, 6 and 18 month and annually to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target vessel revascularization</outcome>
      <timepoint>1 month and at all follow up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stent thrombosis</outcome>
      <timepoint>All follow ups</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neointimal Hyperplasia</outcome>
      <timepoint>6 and 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Binary restenosis</outcome>
      <timepoint>6 and 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>MACE (Major Adverse Cardiac Event)</outcome>
      <timepoint>1 month, 6 month, 18 month and annually to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-segment late lumen loss (LLL) as measured by quantitative coronary angiography</outcome>
      <timepoint>6 and 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-stent late lumen loss (LLL) as measured by quantitative coronary angiography</outcome>
      <timepoint>18 months (optional)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimal Lumen Diameter (MLD), in-stent and in-segment</outcome>
      <timepoint>6 and 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rates of incomplete stent apposition</outcome>
      <timepoint>6 and 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Device success defined as achievement of a final residual diameter stenosis of &lt; 30% measured by QCA, using the study device only.</outcome>
      <timepoint>procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lesion treatment success is defined as &lt;30% residual stenosis measured by QCA by any treatment</outcome>
      <timepoint>Procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Procedure success defined as lesion success without the occurrence of MACE during the hospital stay</outcome>
      <timepoint>discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patient is = 18 years old

          2. Patient is an acceptable candidate for percutaneous coronary intervention (PCI),
             stenting, and emergent coronary artery bypass graft (CABG) surgery

          3. Patient has clinical evidence of ischemic heart disease, stable or unstable angina,
             silent ischemia, and/or a positive functional study

          4. Female subjects of childbearing potential must have a negative pregnancy test within 7
             days before the trial procedure

          5. Patient or subject's legal representative has been informed of the nature of the trial
             and agrees to its provisions and has provided written informed consent as approved by
             the Hospital Research Ethics Committee (HREC) of the respective investigational site

          6. Patient agrees to comply with specified follow-up evaluations and to return to the
             same investigational site where the procedure was performed

        Angiographic:

          1. Patient has either a single target lesion, or two lesions (target and non-target)
             located in separate coronary arteries

          2. If a non-target lesion is treated, it must be treated first and only with commercially
             available PTCA balloons and/or stents. Post PCI of the non-target vessel, all of the
             following conditions must be met:

               -  Residual diameter stenosis &lt;10%

               -  Absence of any angiographic complications

               -  Absence of ischaemic symptoms

               -  Absence of significant new arrhythmia or ECG monitoring changes suggestive of
                  ischaemia

          3. Target lesion must be a de novo lesion in native coronary artery

          4. Target lesion must be = 22 mm in length

          5. Target lesion must have a stenosis of = 50% and &lt; 100%

          6. Target vessel must have a reference vessel diameter (RVD) appropriate for treatment
             with a of 3.0mm or3.5 mm stent

          7. Target vessel must have a Thrombolysis in Myocardial Infarction (TIMI) flow = 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin,
             clopidogrel or ticlopidine, cobalt, chromium, stent coatings (i.e. fatty acids,
             glycerides, and alpha tocopherol), or a sensitivity to contrast media, which cannot be
             adequately pre-medicated

          2. History of an allergic reaction or significant sensitivity to drugs such as ,
             zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative

          3. Platelet count &lt; 100,000 cells/mm³ or &gt; 700,000 cells/mm³, or a white blood cell (WBC)
             count &lt; 3,000 cells/mm³ within 7 days prior to index procedure

          4. Serum creatinine level 170 micromol/L within 7 days prior to index procedure

          5. Evidence of an acute myocardial infarction (MI) within 72 hours of the intended trial
             procedure (defined as: Q wave myocardial infarction (QWMI) or non-Q wave myocardial
             infarction (NQWMI) having CK enzymes &gt; 2X the laboratory upper limit of normal with
             the presence of an elevated CK-MB (any amount above the laboratory upper limit of
             normal)

          6. Previous PCI of the target vessel within 9 months prior to the procedure

          7. Any planned additional PCI procedure within 30 days post-index procedure and/or
             planned PCI of the target vessel within 12 months post-procedure

          8. During the index procedure, the target and/or non-target lesion(s) requires treatment
             with a device other than PTCA prior to stent placement (including, but not limited to,
             cutting balloon, atherectomy, thrombectomy, etc.)

          9. Left ventricular ejection fraction (LVEF) &lt; 30% if evaluated, or clinical evidence of
             significant congestive heart failure (NYHA Class III or IV) within the prior 30 days

         10. History of a stroke or transient ischemic attack (TIA) within the prior 6 months

         11. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months

         12. History of bleeding diathesis or coagulopathy or will refuse blood transfusions

         13. Concurrent medical condition with a life expectancy of less than 12 months

         14. Any previous treatment of the target vessel(s) for restenosis, including brachytherapy

        16. Any condition which, in the Investigator's opinion, may interfere with the subject's
        optimal participation in the study 17. Currently participating in an investigational drug
        or another device trial that has not completed the primary endpoint or that clinically
        interferes with the current trial endpoints; or requires coronary angiography, IVUS or
        other coronary artery imaging procedures

        Angiographic:

          1. Target lesion is located in native vessel distal to anastomosis with a saphenous vein
             graft or a left/right internal mammary artery (LIMA/RIMA) bypass with more than 40%
             diameter stenosis anywhere within the graft

          2. Previous stenting in the target vessel.

          3. The target vessel has other lesions with greater than 40% diameter stenosis based on
             visual estimate or on-line QCA

          4. The target vessel has evidence of thrombus

          5. The target vessel is excessively tortuous (two bends &gt; 90º to reach the target lesion)

          6. The target lesion has any of the following characteristics:

               -  Lesion location is aorto-ostial, an unprotected left main lesion, or within 5 mm
                  of the origin of the left anterior descending (LAD) or left circumflex (LCX)

               -  Involves a side branch &gt; 2.0 mm in diameter

               -  Is at or distal to a &gt; 45º bend in the vessel

               -  Is severely calcified

          7. Unprotected left main coronary artery disease (an obstruction greater than 50% in the
             left main coronary artery)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>31</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Atrium Medical Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate the safety and efficacy of the Cinatra Corolimus Drug Eluting Stent for the
      treatment of de novo lesions in native coronary arteries.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01025869</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John Ormiston, MD</name>
      <address>Associate Professor and Interventional Cardiologist at Auckland City Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>